Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Evolutionary Action Score Identifies a Subset of TP53 Mutated Myelodysplastic Syndrome with Favorable Prognosis

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-141411

Published: 2020

Journal Articles

Only Hotspot SF3B1 K700E Mutation Is an Independent Predictor of Overall Survival in Myelodysplastic Syndromes

Rashmi Kanagal-Shamanna, MD, Guillermo Montalban Bravo, MD, Koji Sasaki, MD, Carlos E. Bueso-Ramos, MD PhD, Elias Jabbour, MD, Yue Wei, PhD, Faezeh Darbaniyan, PhD, Mark Routbort, MD PhD, Sherry A. Pierce, BSN, BA, Kelly A. Soltysiak, PhD, Keyur Patel, MD PhD, L. Jeffrey Medeiros, MD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2020) 136 (Supplement 1): 24–25.

https://doi.org/10.1182/blood-2020-141446

Published: 2020

Journal Articles

Evolutionary Action (EA) Score of TP53 Mutations Defines Prognostic Subsets within TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia

Rashmi Kanagal-Shamanna, MD, Guillermo Montalban-Bravo, MD, Caleb Class, PhD, Koji Sasaki, MD, Christopher B. Benton, MD, Kelly Soltysiak, PhD, Elias Jabbour, MD, Tapan M. Kadia, MD, Carlos E. Bueso-Ramos, MD PhD, Keyur P. Patel, MBBS, PhD, Mark Routbort, MD PhD, Irene Ganan-Gomez, PhD, Yue Wei, PhD, Gautam M. Borthakur, MD, Farhad Ravandi, MD, Kim-Anh Do, PhD, L. Jeffrey Medeiros, MD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2019) 134 (Supplement_1): 1719.

https://doi.org/10.1182/blood-2019-130545

Published: 2019

Journal Articles

The Impact of PHF6 Mutations in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia

Kelly S. Chien, MD, Rashmi Kanagal-Shamanna, MD, Kiran Naqvi, MDMPH, Koji Sasaki, MD, Yesid Alvarado, MD, Koichi Takahashi, MD, Tapan M. Kadia, MD, Gautam M. Borthakur, MD, Elias Jabbour, MD, Mark Routbort, MD PhD, Sherry A. Pierce, BSN, BA, Kelly Soltysiak, PhD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD, Guillermo Montalban-Bravo, MD

Blood (2019) 134 (Supplement_1): 1436.

https://doi.org/10.1182/blood-2019-131188

Published: 2019

Journal Articles

Next-Generation Sequencing of DDX41 in Myeloid Neoplasms Leads to Increased Detection of Germline Alterations

Sarah Bannon, MS, CGC, Mark Routbort, MD PhD, Guillermo Garcia-Manero, MD, Naval G. Daver, MD, Betul Oran, MD MS, Gautam Borthakur, MD, Rohtesh S. Mehta, MD MPH,MS, Kiran Naqvi, MD MPH, Koichi Takahashi, MD, Yesid Alvarado, MD, Tapan M. Kadia, MD, Hagop M. Kantarjian, MD, Keyur P. Patel, MBBS, PhD, Courtney D. DiNardo, MD MSc

Blood (2018) 132 (Supplement 1): 2667.

https://doi.org/10.1182/blood-2018-99-116518

Published: 2018

Journal Articles

Myeloid Malignancy Variant Curation Expert Panel: An ASH-Sponsored Clingen Expert Panel to Optimize and Validate Acmg/AMP Variant Interpretation Guidelines for Genes Associated with Inherited Myeloid Neoplasms

Blood (2018) 132 (Supplement 1): 5849.

https://doi.org/10.1182/blood-2018-99-118979

Published: 2018

Journal Articles

RAS and TP53 , Not NOTCH1 , Can Predict Survival in Adults with Acute T-Cell Lymphoblastic Leukemia Treated with Hypercvad

Ali Sakhdari, MD MSc, Sanam Loghavi, MD, Rashmi Kanagal-Shamanna, MD, C. Cameron Yin, MD PhD, Zhuang Zuo, MD, Mark Routbort, MD PhD, Keyur P. Patel, MBBS, PhD, Raja Luthra, PhD, L. Jeffrey Medeiros, MD, Chi Young Ok, MD

Blood (2018) 132 (Supplement 1): 4085.

https://doi.org/10.1182/blood-2018-99-119017

Published: 2018

Journal Articles

Endleukemia Assay v1: Enabling NGS-Based Comprehensive Routine Molecular Profiling of Leukemias in Routine Clinical Care

Chi Young Ok, MD, Rajesh Singh, PhD, Rajyalakshmi Luthra, PhD, David Hatfield, Kristen Floyd, Sanam Loghavi, MD, Rashmi Kanagal-Shamanna, MD, Zhuang Zuo, C. Cameron Yin, MD PhD, Mark Routbort, MD PhD, Hagop M. Kantarjian, MD, L. Jeffrey Medeiros, MD, Keyur P. Patel, MBBS, PhD

Blood (2017) 130 (Supplement 1): 2679.

https://doi.org/10.1182/blood.V130.Suppl_1.2679.2679

Published: 2017

Journal Articles

Standardized Targeted Sequencing of 29 Genes with Recurrent Mutations in Chronic Lymphocytic Leukemia (CLL) Helps to Better Define Clinical Correlates and Genomic Hotspots

Blood (2017) 130 (Supplement 1): 4304.

https://doi.org/10.1182/blood.V130.Suppl_1.4304.4304

Published: 2017

Journal Articles

Value of Immunohistochemistry-Based Direct Visualization for Localization, Lineage Determination and Monitoring of IDH1 p.R132H Mutant Clones in AML

Habibe Kurt, MD, Carlos E. Bueso-Ramos, MD PhD, Joseph D Khoury, MD, Mark Routbort, MD PhD, Rashmi Kanagal-Shamanna, MD, Jeffrey L. Jorgensen, MD PhD, Courtney D DiNardo, MD, Farhad Ravandi, MD, Hagop M. Kantarjian, MD, Raja Luthra, PhD, Jeffrey Medeiros, MD, Keyur Patel, MD

Blood (2016) 128 (22): 1726.

https://doi.org/10.1182/blood.V128.22.1726.1726

Published: 2016

Journal Articles

Routine Clinical Testing for Actionable Mutations in CLL Using Endcll Assay V1: The Initial MD Anderson Experience

Keyur P. Patel, MD PhD, Rajesh Singh, PhD, Mark Routbort, MD PhD, C. Cameron Yin, MD PhD, Rashmi Kanagal Shamanna, PhD, Nitin Jain, MD, Xinyan Lu, MD, Sherry Pierce, BSN, BA, Michael Keating, MBBS, Hagop M. Kantarjian, MD, L. Jeffrey Medeiros, MD, Raja Luthra, PhD, William G. Wierda, MD PhD

Blood (2016) 128 (22): 3196.

https://doi.org/10.1182/blood.V128.22.3196.3196

Published: 2016

Journal Articles

IKZF3 p.L162R Is a Recurrent Hotspot Mutation in Chronic Lymphocytic Leukemia (CLL)

Koichi Takahashi, MD, Candida Vitale, MD, Carlos Bueso-Ramos, Feng Wang, PhD, Ekaterina Kim, MS, Jianhua Zhang, Curtis Gumbs, Mark Routbort, MD PhD, Zeev Estrov, MD, Nitin Jain, MD, Guillermo Garcia-Manero, MD, Hagop M. Kantarjian, MD, Jan A. Burger, MD PhD, Alessandra Ferrajoli, MD, Michael Keating, MBBS, Andrew Futreal, PhD, William Wierda, MD PhD

Blood (2015) 126 (23): 4136.

https://doi.org/10.1182/blood.V126.23.4136.4136

Published: 2015

Journal Articles

Mutation Analysis in 200 Cases of Newly Diagnosed Myelodysplastic Syndrome By Next Generation Sequencing: Association with Established Prognostic Variables and IPSS-R

Kankana Ghosh, B. Pharm, Parsa Hodjat, MD, Priyanka Priyanka, MPH, Beenu Thakral, MBBS,MD, Keyur P. Patel, MD PhD, Mark Routbort, MD PhD, Rashmi Kanagal-Shamana, MD, C. Cameron Yin, MDPhD, Zhuang Zuo, MD PhD, Raja Luthra, PhD, Tariq Muzzafar, MD

Blood (2015) 126 (23): 1703.

https://doi.org/10.1182/blood.V126.23.1703.1703

Published: 2015

Journal Articles

RAS/RAF Pathway Mutations Define a Distinct Subset of Chronic Lymphocytic Leukemia

Rashmi Kanagal-Shamanna, MD, Raja Luthra, PhD, Madan Luthra, PhD, Xinyan Lu, MD, Mark Routbort, MD PhD, Nitin Jain, MD, Michael Keating, MBBS, L Jeffrey Medeiros, MD, William Wierda, MD PhD, Keyur P. Patel, MD PhD

Blood (2015) 126 (23): 1730.

https://doi.org/10.1182/blood.V126.23.1730.1730

Published: 2015

Journal Articles

Mutation Analysis in 276 Cases of Newly Diagnosed Acute Myeloid Leukemia By Next Generation Sequencing: Association with Established Prognostic Variables and MRC Risk Groups

Parsa Hodjat, MD, Kankana Ghosh, B. Pharm, Priyanka Priyanka, MPH, Beenu Thakral, MBBS,MD, Keyur P. Patel, MD PhD, Mark Routbort, MD PhD, Rashmi Kanagal-Shamana, MD, C. Cameron Yin, MDPhD, Zhuang Zuo, MD PhD, Raja Luthra, PhD, Tariq Muzzafar, MD

Blood (2015) 126 (23): 1392.

https://doi.org/10.1182/blood.V126.23.1392.1392

Published: 2015

Journal Articles

Multigene Mutational Clinical Profiling Using Next Generation Sequencing in a Cohort of 451 Patients with MDS: Impact on Clinical Outcomes

Blood (2014) 124 (21): 4658.

https://doi.org/10.1182/blood.V124.21.4658.4658

Published: 2014

Journal Articles

A Biologically Distinctive Subgroup of Acute Myelogenous Leukemia with Characteristic Nuclear Morphology and a High Frequency of FLT3 Mutation.

Weina Chen, MD, PhD, George Rassidakis, MD, PhD, Mark Routbort, MD, Dan Jones, MD, PhD, L. Jeffrey Medeiros, MD, Carlos Bueso-Ramos, MD, PhD

Blood (2005) 106 (11): 4522.

https://doi.org/10.1182/blood.V106.11.4522.4522

Published: 2005

NARROW

Evolutionary Action Score Identifies a Subset of TP53 Mutated Myelodysplastic Syndrome with Favorable Prognosis

Only Hotspot SF3B1 K700E Mutation Is an Independent Predictor of Overall Survival in Myelodysplastic Syndromes

Evolutionary Action (EA) Score of TP53 Mutations Defines Prognostic Subsets within TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia

The Impact of PHF6 Mutations in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia

Next-Generation Sequencing of DDX41 in Myeloid Neoplasms Leads to Increased Detection of Germline Alterations

Myeloid Malignancy Variant Curation Expert Panel: An ASH-Sponsored Clingen Expert Panel to Optimize and Validate Acmg/AMP Variant Interpretation Guidelines for Genes Associated with Inherited Myeloid Neoplasms

RAS and TP53 , Not NOTCH1 , Can Predict Survival in Adults with Acute T-Cell Lymphoblastic Leukemia Treated with Hypercvad

Endleukemia Assay v1: Enabling NGS-Based Comprehensive Routine Molecular Profiling of Leukemias in Routine Clinical Care

Standardized Targeted Sequencing of 29 Genes with Recurrent Mutations in Chronic Lymphocytic Leukemia (CLL) Helps to Better Define Clinical Correlates and Genomic Hotspots

Value of Immunohistochemistry-Based Direct Visualization for Localization, Lineage Determination and Monitoring of IDH1 p.R132H Mutant Clones in AML

Routine Clinical Testing for Actionable Mutations in CLL Using Endcll Assay V1: The Initial MD Anderson Experience

IKZF3 p.L162R Is a Recurrent Hotspot Mutation in Chronic Lymphocytic Leukemia (CLL)

Mutation Analysis in 200 Cases of Newly Diagnosed Myelodysplastic Syndrome By Next Generation Sequencing: Association with Established Prognostic Variables and IPSS-R

RAS/RAF Pathway Mutations Define a Distinct Subset of Chronic Lymphocytic Leukemia

Mutation Analysis in 276 Cases of Newly Diagnosed Acute Myeloid Leukemia By Next Generation Sequencing: Association with Established Prognostic Variables and MRC Risk Groups

Multigene Mutational Clinical Profiling Using Next Generation Sequencing in a Cohort of 451 Patients with MDS: Impact on Clinical Outcomes

A Biologically Distinctive Subgroup of Acute Myelogenous Leukemia with Characteristic Nuclear Morphology and a High Frequency of FLT3 Mutation.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only